Plant compound tested against a cancer protein in the lab
Original title: Targeting EGFR in cancer using Terminalia arjuna: An integrated In Silico, molecular dynamics, experimental validation, and network pharmacology study.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done on computers and on cells in a dish.
The short version
This is an early lab study of a plant compound aimed at a protein found in some brain tumors.
What was studied. Researchers tested compounds from a plant called Terminalia arjuna. They aimed at EGFR, a protein tied to 20-60% of cancer cases, including glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
What they found. The screen picked out eight compounds from the plant. In computer models, one compound called Arjunapthanoloside gripped EGFR more tightly than a cancer drug. A plant extract also killed oral cancer cells in a dish.
What this means, and what it doesn't
What it could mean: Nothing here changes care today. It is an early hint that this plant may be worth more study. Any real treatment would be many years and many tests away, if it works at all.
What it doesn't mean: This does not mean the plant treats brain tumors. The work was done on computers and on cells in a dish. No people were given anything. The cells used were oral cancer cells, not brain tumor cells. This is not a cure, and it is not a reason to take a supplement.
Source: PubMed, August 18, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.